Spotlight on Presbyopia

Participants: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. View Full Profile Malvina B. Eydelman, MD Dr. Eydelman has been involved in all aspects of assuring the safety and…

Read More

Icon Bioscience

The company’s proprietary Verisome drug delivery technology is being used as the base for IBI-10090, for post-cataract surgery inflammation. The dexamethasone compound completed a pivotal phase 3 study (n=394), and based on these results, Icon plans to file an NDA by late 2015/early 2016. Phase 3 results builds on the phase 2b data, which showed…

Read More

Glaukos

The $4.9 billion glaucoma market is expected to reach $6.6 billion by 2019. The company launched its first product, the iStent, about 2 years ago and has had reasonable market penetration. Further, the company has had tremendous success with getting reimbursement for the device. Prior to the introduction of micro-incisional glaucoma surgery (MIGS), surgery was…

Read More

Spotlight on MIGS – Market Overview

Participant: Eric Donnenfeld, MD Eric Donnenfeld, MD is a founding partner of Ophthalmic Consultants of Long Island, Professor of Ophthalmology NYU and a Trustee at Dartmouth Medical School. View Full Profile

Read More

Ivantis

The Hydrus Microstent dilates and scaffolds Schlemm’s canal. More than 2,000 people in 21 countries have been treated with the Hydrus, and recruitment for the company’s U.S. pivotal trial is now complete (n=558). When in place, the device creates a cross-sectional stent that increases the cross-sectional diameter of Schlemm’s canal by “about 4-5 times,” Van…

Read More

Transcend Medical

The CyPass Micro-Stent has been implanted in more than 1,000 patients over the course of 10 years as part of multiple clinical trials, and Transcend expects to submit to the FDA during 3Q 2105. The device already has the CE Mark, and two post-marketing European studies are ongoing. The CyPass creates a controlled outflow pathway…

Read More

Spotlight on MIGS

Participants: Eric Donnenfeld, MD Eric Donnenfeld, MD is a founding partner of Ophthalmic Consultants of Long Island, Professor of Ophthalmology NYU and a Trustee at Dartmouth Medical School. View Full Profile Richard Lewis, MD Richard A. Lewis, M.D. is the former director of glaucoma at the University of California, Davis before co-founding Sacramento Eye Consultants.…

Read More

Clearsight Innovations

Historically, IOL power formulations are good for average refractive outcomes, but poor for predicting an individual’s refractive outcome. The Mirricon may overcome those issues. The ocular biometer for high-performance IOL power calculations provides “results at the push of a button assuring convenience and easy decisions without great expertise and experience,” Mrochen said. An ongoing proof…

Read More

PowerVision

PowerVision’s FluidVision is a shape-changing accommodating IOL that has been implanted in more than 100 patients to date. As patients focus on near objects, one drop of the lens’ fluid moves from the periphery to the center of the lens, changing its shape. When the patient focuses on a distance object, the reverse occurs. PowerVision…

Read More

Emmetrope

Emmetrope is developing 3 versions of an accommodating lens: single optic ActaLens, dual optic ActaLens-Duo, and shape-changing optic ActaLens-SC, “the future of accommodative lens technology,” said Phillips. To date, small numbers have been enrolled (n=8), but data looks promising—the monofocal hinged silicone ActaLens is injected into the capsular bag through a small corneal incision and…

Read More